Bio-AMD Inc. (fka BIAD)

[BiotechValues]

$BIAD looking like .30s coming next week.

For those new to company, BIAD has the perfect business model- very low cash burn of $70K/month and sits back/collects royalties/licensing fees from multi-billion market cap biotech companies like Sysmex for use of technology that BIAD snatched up for next to nothing out of bankruptcy proceedings.

This is why there's been a lack of dilution in the stock for years, and they have virtually no debt on balance sheet with initial $1M in revenue from Sysmex. That revenue should be recorded in Q1 and is just the start.

This is why BIAD is an investment grade nanocap in my opinion, and it's just beginning to get discovered. The market cap is ridiculous for a biotech company with no dilution, a current ratio of 28 (!) and an agreement with at least one biotech giant.

See current assets vs. current liabilities page 4

https://www.sec.gov/Archives/edgar/data/1370030/000118518514003126/bio-amd10q093014.htm

Then note that revenue is going from "0" in the most recently reported Q to over $1M. When that happens, this board will have hundreds of board marks and BIAD will be discovered. We're in ahead of the market- which is exactly where I like to be!